Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

celecoxib

  • Home
  • celecoxib
Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain
Posted innews Otorhinolaryngology

Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain

Posted by MedXY By MedXY 04/02/2026
A retrospective cohort study of 80 patients undergoing tonsillectomy, adenoidectomy, or uvulopalatopharyngoplasty found that adding celecoxib to multimodal analgesia reduced mean opioid consumption by 44%, while maintaining comparable pain control across postoperative days 1, 5, and 10.
Read More
Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib
Posted inHematology-Oncology news Oncology

Postoperative ctDNA Identifies Stage III Colon Cancer Patients Who May Benefit from Adjuvant Celecoxib

Posted by MedXY By MedXY 12/07/2025
A post hoc analysis of CALGB (Alliance)/SWOG 80702 shows postoperative ctDNA positivity strongly predicts recurrence and suggests adjuvant celecoxib improves DFS and OS in ctDNA-positive stage III colon cancer.
Read More
  • Pulsed Field Ablation Versus Sham Procedure in Atrial Fibrillation: Insights from the PFA-SHAM Randomized Clinical Trial
  • Enhanced Traceability of Breast Implants: Evaluating the Dutch Breast Implant Registry’s Superiority Over Electronic Patient Records in a Test Recall
  • Unraveling Dementia in Severe Schizophrenia: Distinct Cognitive Profiles and Genetic Insights
  • Therapeutic Implications of MARS Therapy-Induced Piperacillin Clearance in Critical Liver Failure Patients
  • Embracing Uncertainty: Integrating Palliative Care into Emergency Medicine Practice
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in